An observational study in Valvular Heart Disease Stenosis and Regurgitation (Diagnosis), Pulmonary Hypertension (Diagnosis) and Heart Failure With Reduced Ejection Fraction (HFrEF; Diagnosis), sponsored by Imperial College London. Recruiting at 6 sites in United Kingdom. Open to participants aged 18 Years to 90 Years. Per ClinicalTrials.gov, last updated 2026-10-08.
Sponsored by Imperial College London · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 53 studies in Gastroesophageal Reflux with a site in United Kingdom — 5 open to participants now, 7 under way, 1 of them phase 3. Gastroesophageal Reflux · United Kingdom.
Among the 53 studies in Gastroesophageal Reflux with a site in United Kingdom, this one is the 2nd largest by planned enrollment of the 19 observational ones that give a count, is one of 3 that started in 2025, is one of 19 observational ones, and was the 50th registered.
1,216 studies on the registry are indexed under Gastroesophageal Reflux; 204 are open to participants now.
Browse Gastroesophageal Reflux studies →5 of the 53 studies in Gastroesophageal Reflux with a site in United Kingdom are open now. Recruiting first, the newest first:
University of Oxford · Sites in United Kingdom
Ages 18+
Medtronic Cardiovascular · Sites in United Kingdom, Denmark, France and 5 more countries
Ages 18+
Cleveland Clinic London · Sites in United Kingdom, Austria, Italy and 4 more countries
Ages 18+
University Hospital Southampton NHS Foundation Trust · Sites in United Kingdom
Ages 18+ · Healthy volunteers
A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →
Of the 134 Gastroesophageal Reflux studies recruiting now, 58 (43%) set no upper age limit and 53 (40%) stop at 75 or younger; 22 take children under 18; 20 take healthy volunteers.
This study: 18 Years to 90 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
53 studies; the count open now beside each. This study's row is marked.
First in 1998; this study’s year is marked. 3 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 590 is above the median of 180 across 349 observational studies indexed under Gastroesophageal Reflux.
Median enrollment 64 across the 32 interventional studies, 199 across the 19 observational. Of the 41 that completed or were terminated, 10 (24%) have results posted.
This tab as a report to print or save as PDF → With an account.
28 of 53 have an industry lead sponsor. The 10 most frequent:
Imperial College London is the lead sponsor of 844 studies on the registry; 181 are open to participants now.
Of its 9 completed or terminated interventional studies of FDA-regulated products, 6 (67%) have results posted.
Imperial College London has 3 studies filed under Gastroesophageal Reflux — fewer than ten, so there is no comparison to draw.
1 of the studies in Gastroesophageal Reflux with a site in United Kingdom that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07057466Imperial College LondonProspective Evaluation of AI-ECG for SHD Detection | 2027-05-03 |
Add it to your calendar (.ics) → With an account.
Among the 53 studies in Gastroesophageal Reflux with a site in United Kingdom, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
AI-ECG-SHD is a multicentre prospective observational diagnostic accuracy study evaluating artificial intelligence-enhanced electrocardiography (AI-ECG) for the detection of structural heart disease in adults undergoing clinically indicated transthoracic echocardiography (TTE).
Participants undergo standard 12-lead ECG acquisition together with ECG recordings obtained using portable or wearable single-, 3-, and 6-lead devices. Established AI-ECG models will be evaluated for the detection of heart failure, pulmonary hypertension and valvular heart disease using TTE as the clinical reference standard, with performance compared across ECG acquisition modalities within the same prospective cohort.
AI-ECG predictions are generated offline and are not provided to treating clinicians or used to alter clinical care. The study will also compare AI-ECG performance with N-terminal pro-B-type natriuretic peptide (NT-proBNP) and evaluate the diagnostic performance of a combined AI-ECG and NT-proBNP approach.
The study aims to recruit 590 participants across six NHS hospital sites. A prespecified subgroup of 203 participants will undergo dedicated venous blood sampling for NT-proBNP; eligible same-day NT-proBNP measurements obtained as part of routine clinical care will also be included where available.
The criteria were revised on the registry on Oct 8, 2026. See what changed
This multicentre prospective observational diagnostic accuracy study will recruit 590 adult inpatients and outpatients aged 18-90 years undergoing transthoracic echocardiography (TTE) as part of routine clinical care.
Participants will be recruited from Chelsea and Westminster Hospital, West Middlesex University Hospital, Hammersmith Hospital, St Mary's Hospital, Bristol Royal Infirmary, and Southmead Hospital.
Patients with known severe structural heart disease are excluded. Patients with previously diagnosed structural abnormalities that do not meet the prespecified severe structural heart disease exclusion criteria may remain eligible for recruitment.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adult inpatients and outpatients undergoing transthoracic echocardiography (TTE) as part of routine clinical care will be recruited prospectively. Participants will undergo study-specific 12-lead ECG acquisition and portable or wearable single-, 3-, and 6-lead ECG recordings. Patients with known severe structural heart disease are excluded, while patients with previously diagnosed structural abnormalities that do not meet the prespecified severe structural heart disease exclusion criteria may remain eligible. AI-ECG predictions will be generated offline and will not inform clinical care.
Other: Traditional 12-lead Electrocardiogram · Other: Apple Watch Series 4 Single-lead Electrocardiogram · Other: Eko Core 500 Digital Stethoscope 3-lead Electrocardiogram · Other: AliveCor KardiaMobile Single- and 6-lead Electrocardiogram
A prespecified subgroup of 203 participants from the overall 590-participant cohort will be selected by stratified randomisation to undergo dedicated venepuncture for measurement of serum NT-proBNP. In addition, eligible same-day NT-proBNP measurements obtained as part of routine clinical care will be included in the NT-proBNP analysis where available. The final NT-proBNP analysis population may therefore exceed the dedicated 203-participant phlebotomy subgroup.
Other: Traditional 12-lead Electrocardiogram · Other: Apple Watch Series 4 Single-lead Electrocardiogram · Other: Eko Core 500 Digital Stethoscope 3-lead Electrocardiogram · Other: AliveCor KardiaMobile Single- and 6-lead Electrocardiogram · Other: Phlebotomy for N-terminal pro-B-type natriuretic peptide
A study-specific standard 12-lead ECG recording will be obtained with the participant in a semi-reclined position. A 10-second ECG will be acquired and pseudonymised for subsequent offline AI-ECG analysis. AI-ECG outputs will not be used to inform or alter clinical care.
A 30-second single-lead ECG will be recorded using an Apple Watch Series 4. The watch will be worn on the participant's left wrist and the participant will place their right index finger on the Digital Crown during recording. The ECG will be used for subsequent offline AI-ECG analysis and will not inform clinical care.
A 30-second 3-lead ECG will be recorded using the Eko CORE 500 digital stethoscope with the participant seated. The device will be positioned over the upper left parasternal region. The ECG will be used for subsequent offline AI-ECG analysis and will not inform clinical care.
Two 30-second ECG recordings will be obtained using the AliveCor KardiaMobile 6L device: a single-lead recording with the participant's thumbs placed on the upper electrodes, followed by a 6-lead recording with the thumbs on the upper electrodes and the lower electrode in contact with the left knee or ankle. Recordings will be used for subsequent offline AI-ECG analysis and will not inform clinical care.
A single 10 mL venous blood sample will be collected from the prespecified subgroup of 203 participants for measurement of serum NT-proBNP. Samples will be analysed by the relevant hospital clinical biochemistry laboratory and disposed of after testing. Eligible same-day NT-proBNP measurements obtained as part of routine NHS care may also be included without an additional blood sample. NT-proBNP results collected for the study will not be used to alter clinical care.
AI-ECG model classification performance for detection of structural heart disease
Diagnostic performance of the AI-ECG models for detection of heart failure (HF), pulmonary hypertension (PH), and valvular heart disease (VHD) will be evaluated separately across conventional 12-lead, derived single-lead, and device-acquired single-, 3-, and 6-lead ECG modalities. The primary measure of model discrimination will be the area under the receiver operating characteristic curve (AUROC).
Time frame: Single study visit on the day of clinically indicated TTE (approximately 30-35 minutes); diagnostic performance calculated following completion of data collection.
Additional AI-ECG performance metrics for detection of structural heart disease
Diagnostic performance will be evaluated separately for each AI-ECG model, disease phenotype, and ECG modality using the area under the precision-recall curve (AUPRC), sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and F1 score.
Time frame: Single study visit on the day of clinically indicated TTE (approximately 30-35 minutes); diagnostic performance calculated following completion of data collection.
Comparison of AI-ECG diagnostic performance across ECG modalities
AI-ECG diagnostic performance will be compared across conventional 12-lead, derived single-lead, and device-acquired single-, 3-, and 6-lead ECG recordings obtained from the same participants. Comparisons will include AUROC and AUPRC, together with sensitivity, specificity, PPV, NPV, and F1 score, for each disease phenotype and ECG modality.
Time frame: Single study visit on the day of clinically indicated TTE (approximately 30-35 minutes); diagnostic performance calculated following completion of data collection.
NT-proBNP diagnostic performance for detection of structural heart disease
The diagnostic performance of NT-proBNP for detection of HF, PH, and VHD will be evaluated against the same echocardiographic reference standards used for AI-ECG. Performance measures will include AUROC, AUPRC, sensitivity, specificity, PPV, NPV, and F1 score.
Time frame: Single study visit on the day of clinically indicated TTE (approximately 30-35 minutes); diagnostic performance calculated following completion of data collection.
Combined AI-ECG and NT-proBNP diagnostic performance
AI-ECG predictions and NT-proBNP will be combined using logistic regression to evaluate the diagnostic performance of a combined digital and biochemical biomarker approach for detection of HF, PH, and VHD. Performance will be assessed using AUROC and AUPRC, with sensitivity, specificity, PPV, NPV, and F1 score also reported for binary model outputs.
Time frame: Single study visit on the day of clinically indicated TTE (approximately 30-35 minutes); diagnostic performance calculated following completion of data collection.
Plan to share: No
No publications or documents are linked to this record.
Started Nov 2025 (actual). Primary completion is estimated for May 2027, 17 months after the start.
Of 95 non-industry observational studies under Gastroesophageal Reflux, half reached primary completion within 57 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 167. This study's planned 17 months is below that.
Counting every sponsor, half of 117 studies reached it within 45 months; a quarter within 17 and three quarters within 134.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.